Trademark: 79211373
Word
ANEMOCYTE
Status
Registered
Status Code
700
Status Date
Tuesday, April 10, 2018
Serial Number
79211373
Registration Number
5440621
Registration Date
Tuesday, April 10, 2018
Mark Type
5000
Filing Date
Monday, February 6, 2017
Published for Opposition
Tuesday, January 23, 2018

Trademark Owner History
ANEMOCYTE S.R.L. - Original Registrant
ARETA INTERNATIONAL S.R.L. - Original Applicant

Classifications
5 Pharmaceutical and veterinary preparations, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for use in human and veterinary medicine; chemical preparations for pharmaceutical or medical purposes, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco skeletal, metabolic diseases, dermatology; prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets, syringes, infusion bags, vials and pharmaceutical preparations for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; biological preparations for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; biological preparations for medical and pharmaceutical use for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; chemical preparations for pharmaceutical purposes, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; preparations for diagnostics for medical purposes; drugs, namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for medical and veterinary purposes; medicines for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; organic products for medical use, namely, natural biomaterials for cell delivery or for augmentation of tissues for medical purposes; biological reagents for medical use; medicinal products based on cells and genes, namely, somatic cells, genes and tissues for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; preparations for diagnostics for medical purposes; drugs namely, recombinant therapeutic proteins, nucleic acids, peptides, cells, genes and tissues for medical and veterinary purposes; medicines for the treatment of disorders in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology; organic products for medical use namely, natural biomaterials for cell delivery or for augmentation of tissues for medical purposes; biological reagents for medical use; medicinal products based on cells and genes, namely, somatic cells, genetically modified cells, viral vectors, nucleic acids and engineered tissues; products for somatic cell therapy, namely, adult stem cells, t-cells, b-cells, nk cells, dendritic cells, monocytes, macrophages, adipocytes, keratinocytes, erythrocytes, platelets, products for gene therapy, namely, genetically modified cells, viral vectors, nucleic acids; tissue engineered products, namely, cells and tissues that have been subjected to extensive manipulation and are used with the aim to repair, replace or restore a lost or impaired tissue or function; products for regenerative medicine, namely, cells and tissues that have been subjected to extensive manipulation and are used with the aim to repair, replace, restore or promote the repair, replacement or regeneration of a lost or impaired tissue or function; products for personalized medicine made of autologous cells or proteins or nucleid acids derived from individual genomic sequences; preparations made up of cells for medical or clinical use; preparations made up of nucleic acids, namely, nucleic acid sequences and chemical reagents for medical purposes; preparations made up of tissues, namely, biological tissue cultures for medical purposes; vaccines; recombinant proteins supplements; therapeutic kits consisting of therapeutic antibodies, buffers, and reagents for use in disease treatment and therapy
42 Services of laboratory analysis and industrial research in the medical and pharmaceutical fields; research and development in the pharmaceutical and biotechnology fields; research and development in the field of micro-organisms and cells; research and development in biochemistry; scientific research and development in biology; research and development in the field of diagnostic preparations; services of medical laboratories; medical information and data on research and development in the medical and veterinary fields; scientific and technological services, namely, scientific research and, literature scientific research in the field of cancer, immunology, heart and lung conditions, infectious diseases, ophthalmology, genito-urinary, central nervous system, musco-skeletal, metabolic diseases, dermatology, consultancy to ensure compliance with quality standards, the design and validation of manufacturing processes
The mark consists of the following: the stylized term "ANEMOCYTE" with the letters "ANEM" and "YTE" appearing in dark grey, and the letters "OC" merged and appearing in light blue, green, blue and light grey.
The color(s) light blue, green, blue, light grey and dark grey is/are claimed as a feature of the mark.

Trademark Events
Apr 9, 2024
Teas Section 71 & 15 Received
Apr 10, 2023
Courtesy Reminder - Sec. 71 (6-Yr) E-Mailed
Oct 24, 2022
Applicant/Correspondence Changes (Non-Responsive) Entered
Oct 24, 2022
Teas Change Of Correspondence Received
Oct 24, 2022
Teas Change Of Domestic Representatives Address
Oct 24, 2022
Teas Withdrawal Of Attorney Received-Firm Retains
Oct 24, 2022
Attorney/Dom.Rep.Revoked And/Or Appointed
Oct 24, 2022
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Oct 24, 2022
Teas Change Of Owner Address Received
Apr 9, 2021
New Representative At Ib Received
Aug 11, 2018
Final Decision Transaction Processed By Ib
Jul 16, 2018
Final Disposition Notice Sent To Ib
Jul 16, 2018
Final Disposition Processed
Jul 10, 2018
Final Disposition Notice Created, To Be Sent To Ib
Apr 10, 2018
Registered-Principal Register
Feb 22, 2018
Change Of Name/Address Rec'd From Ib
Feb 10, 2018
Notification Processed By Ib
Jan 23, 2018
Official Gazette Publication Confirmation E-Mailed
Jan 23, 2018
Published For Opposition
Jan 3, 2018
Notification Of Possible Opposition Sent To Ib
Jan 3, 2018
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Jan 3, 2018
Notification Of Notice Of Publication E-Mailed
Dec 11, 2017
Approved For Pub - Principal Register
Dec 11, 2017
Teas/Email Correspondence Entered
Dec 11, 2017
Correspondence Received In Law Office
Dec 11, 2017
Teas Response To Office Action Received
Oct 20, 2017
Attorney/Dom.Rep.Revoked And/Or Appointed
Oct 20, 2017
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Aug 4, 2017
Refusal Processed By Ib
Jul 18, 2017
Non-Final Action Mailed - Refusal Sent To Ib
Jul 18, 2017
Refusal Processed By Mpu
Jul 12, 2017
Non-Final Action (Ib Refusal) Prepared For Review
Jul 12, 2017
Application Filing Receipt Mailed
Jul 11, 2017
Non-Final Action Written
Jul 8, 2017
Assigned To Examiner
Jul 8, 2017
New Application Office Supplied Data Entered
Jul 7, 2017
Limitation From Original Application Entered
Jul 6, 2017
Sn Assigned For Sect 66a Appl From Ib

Trademark Alertz updated from USPTO on 2030-01-24